DIFFERENCES IN PHENAZEPAM AND ALPRAZOLAM APPLIANCE FOR THE PATIENTS WITH DEPRESSIVE DISORDERS: ETHNIC PECULIARITIES

Abstract

Full Text

Purpose of the work: to conduct a comparative analysis of differences in frequency of prescription of the use of tranquilizers dozes of phenazepam, alprazolam in women who suffer depressive disorders, considering their ethnicity. Materials and methods of the study: we have studied clinical records of female patients of Stavropol Krai Clinical Lunatic Asylum no. 1 (2012-2015), 141 women with depressive disorders, representatives of Slavonic (n=71), Armenian (n=36), Nogai (n=34) ethnic groups. Ethnicity without mixed marriages up to 3rd generation (established in an oral survey) and verified diagnosis of depressive disorders (F30 - F34; by ICD-10) were the insertion criteria into the study. Disregard criteria included 1) age restrictions (not older than 60, the upper limit was conditioned by the aim to reduce the distorting influence on the clinic picture of the main disease); 2) associated diseases, which significantly influence the pharmacokinetics and pharmacodinamics of drugs: heavy affections of liver and kidneys, cholecystitis; 3) endocrine diseases (achrestic diabetes, thyroid gland diseases); 4) heavy somatic disturbances (myocardial infarction etc); 5) addiction to psychoactive substances (alcohol, drug abuse, toxicomania); 6) inflectional diseases - AIDS, HIV infection, tuberculosis, malaria); 7) compulsory treatment; 8) diagnosis of schizophrenia, schizoaffective disorders. We determined 1) frequency of prescriptions - specific weight of patients, who received drugs (%); 2) we conducted a comparative analysis of course, day, single doses of tranquilizers. Results: we have established that phenazepam in the biggest course doses was used by Slavonic patients (25.58±3.93 mg), comparatively less quantities of drugs were used by Nogai patients (2585.71±314.29 mg), the least quantities were used by Armenian patients (15 mg), and comparatively less quantities of the drug were used by Armenian patients (8.67±3.17 mg). The least quantities were used by Slavonic patients. The further analysis revealed that the most prescribed daily doses of phenazepam (1.17±4.64 mg) for the Slavonic female patients with depressions. Comparatively less, in comparison with doses for Slavonic patients, quantity of the drug was used by the representatives of Armenian and Nogai ethnicities. These female patients were prescribed with the drug in similar doses (0.86±0.09 mg). The biggest daily doses of alprazolam were prescribed for Nogai patients (0.5 mg, p<0.05; Kruskal-Wollis criterion), less doses were prescribed for Slavonic women (0.25 mg), the least doses were prescribed for Armenian ethnos (0.21±0.04 mg) The analysis of single doses has shown that phenazepam was used by Slavonic patients in the biggest single dose (0.92±0.11 mg), comparatively less quantity of the drug in comparison with the doses of Slavonic patients, was used by Armenian and Nogai women - the drug was prescribed for these patients at the same doses - 0.86 mg. Alprazolam was prescribed for Slavonic and Nogai women at the same single doses (0.25 mg), Armenian patients received the drug in relatively bigger dose 0.29±0.11 mg. Conclusions: thus, within the framework of the study conducted we have revealed the ethnic peculiarities of the existing psychopharmacotherapy practice with tranquilizers of phenazepam and alprazolam for female patients with depressive disorders - representatives of different ethnicities of Stavropol Krai.